Open Label Safety Study in Acute Treatment of Migraine
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subjects with 2-14 moderate to severe migraines/month
Age of onset of migraines prior to 50 years of age
Migraine attacks, on average, lasting 4-72 hours if untreated
Ability to distinguish migraine attacks from tension/cluster headaches
Patients with contraindications for use of triptans may be included provided they meet all other study entry criteria
History of basilar migraine or hemiplegic migraine
History of HIV disease
History with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia.
Uncontrolled hypertension or uncontrolled diabetes (however, patients can be included who have stable hypertension and /or diabetes for 3 months prior to screening
History of gastric or small intestinal surgery or has a disease that causes malabsorption